Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK,
Adv Ther. 2013 Aug;30(8):713-26. doi: 10.1007/s12325-013-0047-y. Epub 2013 Aug 14.
The management of rheumatoid arthritis has seen a dramatic improvement with the introduction of a range of biological disease modifying anti-rheumatic drugs (DMARDs) in recent years. Nonetheless, a proportion of patients remain resistant or intolerant to multiple conventional and biological DMARDs, so innovative strategies are needed to offer patients new therapeutic options. Tofacitinib is the first of a new class of orally active DMARDs, with immunomodulating effects through inhibition of intracellular Janus kinase (JAK) pathways. It has been recently licensed for treatment of adults with moderate to severe RA in the US, Japan, and Russia. In this review the authors evaluate the efficacy and safety of tofacitinib in RA, focusing predominantly on the phase 3 study data.
近年来，随着一系列生物靶向改善病情抗风湿药（bDMARDs）的问世，类风湿关节炎的治疗取得了显著进展。尽管如此，仍有一部分患者对多种传统和生物 DMARDs 治疗方案反应不佳或不耐受，因此需要创新策略为患者提供新的治疗选择。托法替布是首个新型口服 DMARDs 药物，通过抑制细胞内 Janus 激酶（JAK）通路发挥免疫调节作用。该药最近已在美国、日本和俄罗斯获得批准，用于治疗中重度类风湿关节炎成人患者。本文作者主要评估了托法替布治疗 RA 的疗效和安全性，重点关注了 3 期研究数据。
